Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + oxaliplatin + 5-fluorouracil + calcium folinate
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Liposomal irinotecan + oxaliplatin + 5-fluorouracil (5-FU) + calcium folinate (leucovorin) is a four-drug chemotherapy regimen primarily used as first-line treatment for metastatic pancreatic ductal adenocarcinoma. Liposomal irinotecan is a topoisomerase I inhibitor encapsulated in a lipid nanoparticle to improve delivery and reduce toxicity. Oxaliplatin is a platinum-based DNA crosslinker that induces apoptosis. 5-Fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis. Calcium folinate enhances the binding of 5-FU to its target enzyme, increasing efficacy. The combination has demonstrated improved progression-free and overall survival compared to other regimens in clinical trials[1][6][8]. The regimen is also known as NALIRIFOX when using the liposomal formulation of irinotecan.
- Brand names
- Onivyde (for liposomal irinotecan)
- Other names
- nal-IRI/oxaliplatin/5-FU/LVliposomal irinotecan, oxaliplatin, fluorouracil, and leucovorinNALIRIFOX regimen
02
Targets
TOP1 (DNA Topoisomerase I)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on liposomal irinotecan + oxaliplatin + 5-fluorouracil + calcium folinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + oxaliplatin + 5-fluorouracil + calcium folinate.